Skip to main content

Phase 1 Immunology & Autoimmune Deal Benchmarks

Median Upfront
$139M
Range: $64M - $215M
Total Deal Value
$1.3B
Range: $706M - $1.9B
Royalty Rate
8.8% - 15.3%
Tiered up to 19.3%
Dev Milestones
$400M
Range: $225M - $576M

Market Analysis

Phase 1 immunology & autoimmune licensing deals carry a median total deal value of $1.3B, with upfront payments ranging from $64M to $215M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 11% to upfront and 89% to milestones.

The immunology & autoimmune landscape at the phase 1 stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $400M, regulatory milestones contribute $400M, and commercial milestones reach $343M. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.

Royalty rates for phase 1 immunology & autoimmune deals range from 8.8% to 15.3% at the base tier, with high-tier escalation to 19.3%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1 immunology & autoimmune deals?
Phase 1 immunology & autoimmune deals average $139M in upfront payments, ranging from $64M to $215M. The upfront allocation of 11% of total deal value reflects the clinical stage risk profile.
How are phase 1 immunology & autoimmune deal milestones structured?
Milestones account for approximately 89% of total deal value. Development milestones ($400M) represent the largest component, followed by commercial milestones ($343M) and regulatory milestones ($400M).
What royalty rates are typical for phase 1 immunology & autoimmune licensing?
Base royalty rates range from 8.8% to 15.3%, with tiered escalation to 12.8%-19.3% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included